Search Results - "Loftus Jr, E V"

The effects of itraconazole on inflammatory bowel disease activity in patients treated for histoplasmosis by Samuel, S., Loftus Jr, E. V., Sandborn, W. J.

Get full text

Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients by Mohabbat, A. B., Sandborn, W. J., Loftus Jr, E. V., Wiesner, R. H., Bruining, D. H.

“…Summary Background Ulcerative colitis (UC) and Crohn's disease can sometimes relapse and be refractory to standard treatment following orthotopic liver…”
Get full text

Letter: the definition of budesonide dependence in microscopic colitis—authors’ reply by Cotter, T. G., Kamboj, A. K., Hicks, S. B., Tremaine, W. J., Loftus Jr, E. V., Pardi, D. S.

“…Linked ContentThis article is linked to Cotter et al and Fernández‐Bañares and Gisbert papers. To view these articles visit https://doi.org/10.1111/apt.14133…”
Get full text

Evolving Molecular Targets in the Treatment of Nonmalignant Gastrointestinal Diseases by Katzka, D A, Loftus Jr, E V, Camilleri, M

“…Novel treatments for gastrointestinal (GI) diseases are based on molecular targets. Novel pharmacologic and biological agents with greater selectivity and…”
Get full text

Crohn's disease in Olmsted County, Minnesota, 1940–1993: Incidence, prevalence, and survival by Loftus, Edward V., Silverstein, Marc D., Sandborn, William J., Tremaine, William J., Harmsen, W.Scott, Zinsmeister, Alan R.

“…Background & Aims: Many centers worldwide have reported an increased incidence of Crohn's disease, but population-based data in North America are sparse. We…”
Get full text

Risk of lymphoma in inflammatory bowel disease by Loftus, Edward V., Tremaine, William J., Habermann, Thomas M., Harmsen, Scott W., Zinsmeister, Alan R., Sandborn, William J.

“…Inflammatory bowel disease with a subsequent diagnosis of non-Hodgkin's lymphoma has been reported. There is concern that the risk of developing lymphoma will…”
Get full text

Systematic review: colitis associated with anti‐CTLA‐4 therapy by Gupta, A., De Felice, K. M., Loftus, E. V., Khanna, S.

“…Summary Background Cytotoxic T‐lymphocyte‐associated protein‐4 (CTLA‐4) has an important role in T‐cell regulation, proliferation and tolerance. Anti‐CTLA‐4…”
Get full text

Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease by Moon, W., Loftus, E. V.

“…Summary Background Azathioprine and mercaptopurine have a pivotal role in the treatment of inflammatory bowel disease (IBD). However, because of their complex…”
Get full text

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target by Peyrin-Biroulet, L, Sandborn, W, Sands, B E, Reinisch, W, Bemelman, W, Bryant, R V, D'Haens, G, Dotan, I, Dubinsky, M, Feagan, B, Fiorino, G, Gearry, R, Krishnareddy, S, Lakatos, P L, Loftus, Jr, E V, Marteau, P, Munkholm, P, Murdoch, T B, Ordás, I, Panaccione, R, Riddell, R H, Ruel, J, Rubin, D T, Samaan, M, Siegel, C A, Silverberg, M S, Stoker, J, Schreiber, S, Travis, S, Van Assche, G, Danese, S, Panes, J, Bouguen, G, O'Donnell, S, Pariente, B, Winer, S, Hanauer, S, Colombel, J-F

“…The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory…”
Get full text

Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease by Tse, C. S., Loftus, E. V., Raffals, L. E., Gossard, A. A., Lightner, A. L.

“…Summary Background Primary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic biliary disease associated with inflammatory bowel disease (IBD)…”
Get full text

Systematic review with meta‐analysis: faecal diversion for management of perianal Crohn's disease by Singh, S., Ding, N. S., Mathis, K. L., Dulai, P. S., Farrell, A. M., Pemberton, J. H., Hart, A. L., Sandborn, W. J., Loftus, E. V.

“…Summary Background Temporary faecal diversion is sometimes used for management of refractory perianal Crohn's disease (CD) with variable success. Aims To…”
Get full text

Postoperative outcomes in vedolizumab‐treated Crohn's disease patients undergoing major abdominal operations by Lightner, A. L., McKenna, N. P., Tse, C. S., Raffals, L. E., Loftus, E. V., Mathis, K. L.

“…Summary Background Up to 80% of patients with Crohn's disease require an abdominal operation in their lifetime. As the use of vedolizumab is increasing for the…”
Get full text

Comparison of infliximab with adalimumab in 827 biologic‐naïve patients with Crohn's disease: a population‐based Danish cohort study by Singh, S., Andersen, N. N., Andersson, M., Loftus, E. V., Jess, T.

“…Summary Background There are conflicting data on comparative effectiveness of adalimumab and infliximab in patients with Crohn's disease (CD). Aims To compare…”
Get full text

P734 Super-responders in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab maintenance therapy: A post hoc analysis of the LIBERTY-CD study by Schreiber, S W, Sands, B E, Hanauer, S B, Danese, S, Loftus Jr, E V, Jeong, A L, Kim, D H, Lee, Y N, Colombel, J F

“…Abstract Background The LIBERTY-CD study demonstrated a broad level of benefit for subcutaneous (SC) infliximab (IFX) maintenance therapy compared with placebo…”
Get full text

P540 Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: An analysis of the phase 2 OASIS and phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials by Lees, C, Torres, J, Leung, Y, Vermeire, S, Fellmann, M, Modesto, I, McDonnell, A, Lazin, K, Keating, M, Goetsch, M, Wu, J, Loftus Jr, E V

“…Abstract Background Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to…”
Get full text

Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis by Peyrin-Biroulet, L., Bossuyt, P., Bettenworth, D., Loftus, E. V., Anjie, S. I., D’Haens, G., Saruta, M., Arkkila, P., Park, H., Choi, D., Kim, D- H., Reinisch, W.

“…Background Infliximab and vedolizumab are widely used to treat Crohn’s disease (CD) and ulcerative colitis (UC). Aims This systematic review and network…”
Get full text

P786 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes in patients with Crohn’s disease by Panés, J, Louis, E, Bossuyt, P, Joshi, N, Lee, W J, Lacerda, A, Remple, V, Xuan, S, Loftus Jr, E V

“…Abstract Background STRIDE-II guidelines recommend endoscopic healing as an important treatment goal in Crohn’s disease (CD). This study evaluated the…”
Get full text

P439 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn’s disease by Panés, J, Louis, E, Bossuyt, P, Joshi, N, Lee, W J, Lacerda, A, Remple, V, Xuan, S, Loftus Jr, E V

“…Abstract Background Patients with Crohn’s disease (CD) experience reduced quality of life (QoL), and disease-related impact on work productivity, contributing…”
Get full text

P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative Colitis by Peyrin-Biroulet, L, Bossuyt, P, Bettenworth, D, Loftus Jr, E V, Anjie, S, D’Haens, G, Saruta, M, Arkkila, P, Kim, D H, Choi, D, Reinisch, W

“…Abstract Background Network meta-analysis (NMA) using randomised controlled trial (RCT) data can provide indirect evidence on comparative efficacy of various…”
Get full text

P854 Race and ethnicity in ulcerative colitis clinical trial enrolment: a post hoc analysis of patient demographics and clinical characteristics from GEMINI 1, VARSITY, and VISIBLE 1 by Khan, R M Q, Ananthakrishnan, A N, Loftus Jr, E V, Iroku, U, Mukherjee, R, Uddin, S, Odufalu, F D, Liu, J

“…Abstract Background The incidence of inflammatory bowel disease (IBD) has risen among Black individuals and Hispanic or Latino individuals in the USA in recent…”
Get full text